A Review of the Current Evidence Connecting Seborrheic Dermatitis and Parkinson's Disease and the Potential Role of Oral Cannabinoids

Dermatology. 2021;237(6):872-877. doi: 10.1159/000512189. Epub 2020 Dec 17.


Parkinson's disease (PD) is a neurodegenerative disorder associated with multiple comorbidities, including seborrheic dermatitis (SD), which develops in more than half of PD patients. SD in patients with PD can be severe and frequently intractable by traditional topical therapy. Cannabinoids possess anti-inflammatory and neuromodulatory properties working within the intrinsic endocannabinoid system, the activation of which may alleviate the motor symptoms of PD. The effect of cannabinoids on SD is unknown. Here we explore the pathophysiological mechanisms and possible therapeutic role of oral cannabinoids in PD patients with SD, and review speculative mechanisms underlying the association of PD and SD. Current data supporting the use of cannabinoids in both PD and SD, as well as oral cannabinoid safety and tolerability, are presented. Cannabinoids may provide the possibility of simultaneous treatment of both SD and PD. Specific SD studies and additional safety data on oral cannabinoids are needed.

Keywords: Cannabidiol; Cannabinoids; Neurocutaneous pathway; Parkinson’s disease; Seborrheic dermatitis.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Cannabinoids / therapeutic use*
  • Dermatitis, Seborrheic / complications
  • Dermatitis, Seborrheic / drug therapy*
  • Humans
  • Parkinson Disease / complications
  • Parkinson Disease / drug therapy*


  • Cannabinoids